Expediting Next-Generation Vaccine Development Using Advanced Analytical Methods

The emergence of the COVID-19 pandemic has spurred wide interest in the development of new and novel vaccines and therapeutic drugs against viruses. In addition to the classical platforms (whole-inactivated virus; live-attenuated virus; protein subunit and virus-like particles), novel next-generation platforms (viral vector, DNA, RNA, and antigen-presenting cells) are some of the emerging areas.

Explore how the COVID-19 pandemic has brought to the fore novel analytical methods to ensure speed and efficacy throughout the rollout process. This article is taken from European Biopharmaceutical Review April 2021, pages 20 - 24.